Key statistics
As of last trade Arcus Biosciences Inc (RCUS:NYQ) traded at 14.75, 9.30% above its 52-week low of 13.50, set on Nov 27, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 14.95 |
---|---|
High | 15.40 |
Low | 14.69 |
Bid | 14.74 |
Offer | 14.76 |
Previous close | 14.70 |
Average volume | 606.63k |
---|---|
Shares outstanding | 91.51m |
Free float | 54.36m |
P/E (TTM) | -- |
Market cap | 1.35bn USD |
EPS (TTM) | -3.15 USD |
Data delayed at least 15 minutes, as of Nov 25 2024 17:51 GMT.
More ▼
- Arcus Biosciences to Participate in Two Upcoming Investor Conferences
- Arcus Biosciences Announces New Employment Inducement Grants
- Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update
- Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer
- Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting
- First Clinical Data for Arcus Biosciences’ HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer
- Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update
- Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium
- Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma
- Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital
More ▼